The biotechnology company ChromaDex Corporation (CDXC) continued the rally after ring of the bell on Thursday rising +18.68%. During the regular session price of the stock skyrocketed 92.40% concluding at $18.74.
What is causing the surge?
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
The ChromaDex Corporation is a global bioscience company with a passion for healthy aging. Research at ChromaDex leads the way in pioneering studies of nicotinamide, a nutrient that becomes depleted with age. ChromaDex is regarded as the inventor of nicotinamide riboside (NR), the active form of NAD+, and other NAD+ precursors, which is in ChromaDex’s patent portfolio.
ChromaDex Corp. reveals results from its study on “Combined Metabolic Activators Accelerates Recovery in Mild-to-Moderate COVID-19” on Wednesday. A preprint of these studies appeared on the medRxiv website on Feb. 20. An added nutritional protocol to standard treatment reduced recovery time by 3.5 days in patients with mild-to-moderate COVID-19 when compared to standard care.
Researchers with the ChromaDex External Research Program (CERP) and ScandiBio Therapeutics have followed up findings from Phase 2 clinical data published in October 2020 with the findings from the current study. With the introduction of the nutritional protocol, or combined metabolic activators (CMA), into the Turkish standard of care, recovery time declined and liver health improved, as well as markers of inflammation declined.
Researchers examined 309 outpatient patients at Umraniye Teaching and Research Hospital, University of Health Sciences, Istanbul, Turkey, in a Phase 3 randomized, placebo-controlled and double-blind clinical trial. The Nutritional Protocol or Placebo was given on a three-to-one basis in combination with either hydroxychloroquine (HCQ) or favipiravir (FP). For five days patients were given standard care, and then the nutritional protocol or placebo for two weeks.
The publication of an achievement towards treatment of COVID-19 caused the stock price to almost double its value in a day on Thursday, and the surge remain even after ring of the bell on the day.